5 unchanged sentences
(c) Purchases of Equity Securities by the Issuer
−Removed: The following table reflects share repurchases of our common stock for the three months ended March 31, 2023.
+Added: The following table reflects share repurchases of our common stock for the three months ended June 30, 2023.
Total Number of Shares Purchases
2 unchanged sentences
Approximate Dollar Value of Shares That May Yet Be Purchased Under the Plans or Programs
−Removed: January 1, 2023 to January 31, 2023
−Removed: February 1, 2023 to February 28, 2023
−Removed: March 1, 2023 to March 31, 2023
+Added: April 1, 2023 to April 30, 2023
+Added: May 1, 2023 to May 31, 2023
+Added: June 1, 2023 to June 30, 2023
+Added: (1) On October 31, 2022, our board of directors authorized a new share repurchase program under which we may repurchase up to
+Added: $100.0 million of our outstanding shares of common stock.
+Added: The repurchase program authorizes the repurchase by the Company of its common stock in open market transactions, including pursuant to a trading plan in accordance with Rule 10b-18 promulgated under the Exchange Act, privately negotiated transactions, in block trades, accelerated share repurchase transactions, exchange transactions, or any combination thereof or by other means in accordance with federal securities laws.
+Added: The authorization permits management to repurchase shares of the Company’s common stock from time to time at management’s discretion.
+Added: Repurchases may also be made pursuant to a trading plan under Rule 10b5-1 under the Exchange Act, which would permit shares to be repurchased when the Company might otherwise be precluded from doing so because of self-imposed trading blackout periods or other regulatory restrictions.
+Added: The actual means and timing of any shares purchased under the program will depend on a variety of factors, including ongoing assessments of the capital needs of the business, the market price of our common stock, prevailing stock prices, general market conditions and other considerations.
+Added: This program has no termination date, may be suspended or discontinued at any time at our discretion, and does not obligate us to acquire any amount of common stock.
D efaults Upon Senior Securities
4 unchanged sentences
Amended and Restated Certificate of Incorporation
−Removed: Certificate of Amendment of Restated Certificate of Incorporation
−Removed: Certificate of Ownership and Merger Merging LABA Merger Sub, Inc.
−Removed: with and into Theravance, Inc., as filed with the Secretary of State of the State of Delaware, effective on January 7, 2016
−Removed: Amended and Restated Bylaws, amended and restated as of February 8, 2017
Amended and Restated Bylaws, amended and restated as of January 1, 2023
6 unchanged sentences
Indenture (including form of Note) with respect to Innoviva’s 2.125% Convertible Senior Notes due 2028, dated as of March 7, 2022, between Innoviva and The Bank of New York Mellon Trust Company, N.A., as trustee
−Removed: Transition Agreement between Larry Edwards and Innoviva Specialty Therapeutics, Inc., dated February 23, 2023, and Release of Claims form signed by Larry Edwards, dated April 5, 2023
+Added: 2023 Employee Stock Purchase Plan
Certification of Principal Executive Officer pursuant to Rules 13a‑14 pursuant to the Securities Exchange Act of 1934
13 unchanged sentences
Innoviva, Inc.
+Added: August 2, 2023
/s/ Pavel Raifeld
2 unchanged sentences
(Principal Executive Officer)
+Added: August 2, 2023
/s/ Marianne Zhen
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.